Want to join the conversation?
Millendo Therapeutics said it has entered into an exclusive license agreement with $AZN for worldwide development and commercialization rights to AZD4901, product candidate for treatment of polycystic ovary syndrome (PCOS), the most common endocrine disease in women. Millendo will develop the compound as MLE4901.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.